GD Awarded $42 M to Support US Army Medical Research and Development Programs
General Dynamics Information Technology, a business unit of General Dynamics (NYSE: GD), was awarded a $41.8 million task order by the U.S. Army Medical Research Materiel Command to provide support services for vaccine, drug and medical device development programs to the U.S. Army Medical Materiel Development Activity. This task order was awarded under the TRICARE Evaluation, Analysis and Management Support (TEAMS) contract vehicle and has a term of four years and seven months. USAMMDA is the U.S. Department of Defense’s advanced medical materiel development activity for products designed to protect and preserve the lives of service members.
General Dynamics will deliver a wide range of services to help the USAMMDA guide new medical technologies through the U.S. Food and Drug Administration regulatory and certification process and develop plans to bring these new products into service. General Dynamics has partnered with Tunnell Government Services Inc., a life sciences technical services consulting leader in biotechnology, medical devices and pharmaceutical product development, on this contract. The companies will provide health, medical research, clinical trial and regulatory expertise as well as information, acquisition and program management support services.
The Global Armored and Counter IED Vehicles Market 2014-2024
“Medical research plays a critical role in ensuring that U.S. servicemen and servicewomen are protected before, during and after a mission,” said Marcus Collier, senior vice president, Health and Civilian Solutions division, General Dynamics Information Technology. “Our unique combination of health, military and IT expertise will help the USAMMDA develop new leading-edge medical solutions.”
General Dynamics anticipates hiring more than 30 new employees to perform this work at Fort Detrick in Frederick, Md. The company has supported the USAMMDA for four years under a task order issued by the U.S. Army Medical Research Acquisition Activity.
USAMMDA develops new drugs, vaccines and medical support devices that enhance readiness, ensure provisions of the highest quality medical care to the DoD and maximize the survival of medical casualties on the battlefield. The product managers at USAMMDA guide promising new concepts and technologies developed in the USAMRMC laboratories through advanced development and the regulatory process to obtain U.S. FDA certification. Upon FDA certification, USAMMDA works in conjunction with the U.S. Army Medical Materiel Agency to develop plans for fielding medical materiel.
Your company’s press release on ASDNews and to thousands of other journalists and editors? Use our ASDWire press release distribution service.
Source : General Dynamics Corporation (NYSE: GD)
May 23 - 24, 2016 - Singapore, Singapore